

1 SCIENTIFIC COMMENTARY

2 **A cholinergic contribution to postural control and freezing of gait in**
3 **Parkinson's disease**

4 **This scientific commentary refers to 'Cholinergic system correlates of postural control**
5 **changes in Parkinson's disease freezers' by Roytman *et al.***
6 **(<https://doi.org/10.1093/brain/awad134>).**

7
8 Gait disorders and their consequences—most notably falls—are common manifestations of ageing
9 and age-associated conditions such as Parkinson's disease, and adversely affect quality of life.
10 Progressive and specific degeneration of the cholinergic system is widely implicated in
11 Parkinson's disease, and may underpin the discrete gait impairments that are present even at
12 disease diagnosis. One of the most debilitating gait difficulties in Parkinson's disease is freezing
13 of gait (FoG), which is characterised by the failure of step initiation or turning on walking, and
14 which becomes increasingly problematic as the disease progresses. FoG increases the risk of falls
15 and is associated with neuropsychiatric symptoms such as apathy as well as with reduced quality
16 of life.¹

17
18 Molecular imaging methods using the PET radiotracer [¹⁸F]-fluroethoxybenzovesamicol
19 (FEOBV), which has a high binding affinity and selectivity for the vesicular acetylcholine
20 transporter (VAChT), have shown reduced VAChT expression in striatal cholinergic interneurons,
21 in addition to limbic archicortical structures, in patients with Parkinson's disease and FoG,
22 highlighting higher level cortical dysfunction.² These findings were distinct from the thalamic
23 cholinergic deficits seen in individuals with frequent falls, and have potential implications for
24 treatment targets.² To date, there is disagreement as to how postural instability and FoG are related:
25 there is some evidence that postural instability may be reinforced and intensified by FoG, or vice
26 versa; conversely it has been argued that the two may share similar neurobiological mechanisms
27 without being fundamentally related.³ In this issue of *Brain*, Roytman and colleagues address some
28 of these uncertainties by comparing novel postural control features, as measured using

1 computerized posturography, between freezers and non-freezers, and by determining any
2 association with cholinergic integrity as assessed by acetylcholinesterase PET.⁴ They postulate a
3 shared cholinergic pathology underpinning both FoG and impaired postural control in people with
4 Parkinson's disease, mediated by disruption to multisensory-motor and cognitive processing.

5
6 The authors assessed performance on a posture test platform called the Equitest Sensory
7 Organization Test (SOT) (NeuroCom© International, Inc. [Clackamas, OR, USA]) in both freezers
8 and non-freezers in the OFF state. The SOT can determine reliance on visual, proprioceptive and
9 vestibular cues in maintaining postural stability under conditions of varying visual input (eyes
10 open/eyes closed), plate movement (fixed or sway), surround environment (fixed or sway-
11 referenced) and sensory input (proprioceptive, visual, and vestibular). The authors then used
12 acetylcholinesterase PET to examine whether any differences between freezers and non-freezers
13 in postural control metrics were associated with cholinergic dysfunction.

14
15 The principal findings from the study were firstly that those with FoG were more reliant on
16 proprioceptive cues, with differences between the freezer and non-freezer groups most evident
17 when proprioceptive cues were rendered unreliable, highlighting the importance of visual-
18 vestibular cues for maintaining postural control in freezers. Secondly, the most consistent predictor
19 of freezer status in terms of exact postural control features was critical mean square displacement
20 in the anterior-posterior axis, increases of which can be regarded as an overall reduction in the
21 effectiveness of postural adjustments for maintenance of stability. As this feature plus the critical
22 time interval (time taken for sensory information to travel, integrate with other modalities and be
23 utilised via top-down postural control mechanisms) increased in freezers in the absence of reliable
24 proprioceptive cues, the authors postulated that greater impairments in vestibular processing might
25 lead to difficulties reconciling conflict between visual and vestibular sensory cues in those with
26 FoG. This complements recent imaging work from the same group, where reduced cholinergic
27 integrity of vestibular sensory conflict deficits in Parkinson's disease localised to structures
28 involved in multi-sensory—particularly vestibular sensory—processing.⁵ Vestibular sensory
29 conflict deficit-associated cholinergic terminal loss had the strongest association with FoG status,
30 followed by a history of postural instability and falls. Finally in their current study, the authors

1 showed that right cortical cholinergic network changes underpinned balance during visual-
2 vestibular conflict; changes which were destabilised by a greater anticholinergic burden.

3
4 Limitations of the study include the inability of acetylcholinesterase PET tracer to assess critical
5 structures involved in visual-vestibular integration of postural control, including the cerebellum.
6 Recent work using functional MRI with motor and visual imagery highlighted the importance of
7 several cerebellar regions in freezers compared to non-freezers, with increased activation in the
8 cerebellum in Parkinson's disease without FoG compared to controls.⁹ This increased activation
9 in non-freezers may be analogous to the compensatory upregulation of hippocampal cholinergic
10 innervation in Parkinson's disease with normal cognition compared to Parkinson's disease with
11 mild cognitive impairment,⁷ and has implications for blanket pro-cholinergic treatment in this
12 heterogeneous disease.

13
14 Notwithstanding the PET tracer limitation, the study by Roytman *et al.* highlights the importance
15 of the right cortical cholinergic system in postural control in Parkinson's disease, particularly with
16 respect to maintaining stability under challenging conditions. A key clinical—and potentially
17 actionable—take home message is that an anticholinergic burden score of ≥ 3 (for example, the
18 prescription of amitriptyline at any dose) was associated with suppression of this right cortical
19 cholinergic system and increased postural instability independent of motor disease and freezer
20 status. Drugs with anticholinergic burden are commonly prescribed for non-motor symptoms such
21 as overactive bladder, pain and hypersalivation in Parkinson's disease; the potential risks should
22 be carefully discussed with patients at prescription, particularly with multiple drugs.

23
24 Finally, this work adds to the notion that personalised pro-cholinergic interventions may be helpful
25 in the management of gait and balance disorders in Parkinson's disease. A large interventional
26 study of cholinesterase inhibitors in falls in Parkinson's disease has just reached its recruitment
27 target,⁸ with FoG as a secondary outcome measure; the results of this study will be informative in
28 future management of advanced Parkinson's disease. Studies of novel non-pharmacological
29 interventions such as non-invasive vagus nerve stimulation, which targets potentially

1 cholinergically mediated gait impairments, are also underway.⁹ Additional promising therapeutic
2 non-invasive and neuromodulatory interventions that are relevant to the current study include
3 caloric vestibular stimulation and targeting the acetylcholine-dependent microbiome through the
4 gut-brain axis.¹⁰ A better understanding of the nuances of cholinergic dysfunction and a
5 personalised approach to treatment strategies is key to improving the management of debilitating
6 symptoms in Parkinson's disease.

7

8 *Alison J. Yarnall^{1,2} and Rosie Morris³*

9 *1 Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle*
10 *University, UK*

11 *2 Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK*

12 *3 Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon*
13 *Tyne, UK*

14

15 Correspondence to: Alison J. Yarnall

16 E-mail: alison.yarnall@newcastle.ac.uk

17

18 **Competing interests**

19 The authors report no competing interests.

20

21

22 **Funding**

23 A.J.Y. is supported by the NIHR Newcastle Biomedical Research Centre (BRC). She has received
24 funding from Dunhill Medical Trust, EU IMI, NIHR, Parkinson's UK, Michael J Fox Foundation,
25 Weston Brain Institute, Intercept pharmaceuticals, and the Lewy Body Society.

26

1 The NIHR Newcastle Biomedical Research Centre (BRC) is a partnership between Newcastle
2 Hospitals NHS Foundation Trust, Newcastle University, and Cumbria, Northumberland and Tyne
3 and Wear NHS Foundation Trust and is funded by the National Institute for Health and Care
4 Research (NIHR). The views expressed are those of the authors and not necessarily those of the
5 NIHR or the Department of Health and Social Care.

6

7

8

9 **References**

- 10 1. Perez-Lloret S, Negre-Pages L, Damier P, et al. Prevalence, determinants, and effect on
11 quality of life of freezing of gait in Parkinson disease. Multicenter Study. *JAMA Neurology*. Jul 01
12 2014;71(7):884-90.
- 13 2. Bohnen NI, Kanel P, Zhou Z, et al. Cholinergic system changes of falls and freezing of gait
14 in Parkinson's disease. *Ann Neurol*. 04 2019;85(4):538-549.
- 15 3. Bekkers EMJ, Dijkstra BW, Heremans E, Verschueren SMP, Bloem BR, Nieuwboer A.
16 Balancing between the two: Are freezing of gait and postural instability in Parkinson's disease
17 connected? *Neurosci Biobehav Rev*. 11 2018;94:113-125.
- 18 4. Roytman S, Paalanen R, Griggs A, et al. Cholinergic system correlates of postural control
19 changes in Parkinson's disease freezers. *Brain*. Published online 22 April 2023.
20 doi:10.1093/brain/awad134
- 21 5. Bohnen NI, Kanel P, Roytman S, et al. Cholinergic brain network deficits associated with
22 vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait
23 deficits. *Journal of Neural Transmission*. 08 2022;129(8):1001-1009.
- 24 6. Dijkstra BW, Gilat M, D'Cruz N, Zoetewei D, Nieuwboer A. Neural underpinnings of
25 freezing-related dynamic balance control in people with Parkinson's disease. *Parkinsonism Relat*
26 *Disord*. 2023;doi:10.1016/j.parkreldis.2023.105444

- 1 7. Legault-Denis C, Aghourian M, Soucy JP, et al. Normal cognition in Parkinson's disease
2 may involve hippocampal cholinergic compensation: An exploratory PET imaging study with
3 [(18)F]-FEOBV. *Parkinsonism Relat Disord.* Oct 2021;91:162-166.
4 doi:10.1016/j.parkreldis.2021.09.018
- 5 8. Neumann S, Taylor J, Bamford A, et al. Cholinesterase inhibitor to prevent falls in
6 Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial
7 of rivastigmine to prevent falls in Parkinson's disease. *Bmc Neurol.* Oct 29 2021;21(1)doi:ARTN
8 42210.1186/s12883-021-02430-2
- 9 9. Sigurdsson HP, Hunter H, Alcock L, et al. Safety and tolerability of adjunct non-invasive
10 vagus nerve stimulation in people with parkinson's: a study protocol. *Clinical Trial Protocol. BMC*
11 *Neurol.* Feb 03 2023;23(1):58.
- 12 10. Bohnen NI, Yarnall AJ. Emerging non-invasive therapeutic approaches targeting
13 hypocholinergic neural systems in Parkinson's disease. *Neural Regen Res.* Apr 2023;18(4):809-
14 810. doi:10.4103/1673-5374.353490

15
16